Opinion|Videos|October 9, 2024
Integrating Support Services and Caregiver Roles in mCRC Care
Key Takeaways
- Patients in the third-line stage of mCRC experience anxiety, fear, and uncertainty, impacting treatment decision-making.
- Early involvement of support services, such as social work and palliative care, is crucial for addressing psychosocial challenges.
Medical experts explore the psychological and emotional aspects of decision-making for patients in the third-line stage of metastatic colorectal cancer, recommend involving support services like social work or palliative care, and discuss the caregiver’s role in supporting patients through these psychosocial challenges.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- To set the stage, what are some of the psychological and emotional aspects of treatment decision-making with patients entering the third-line stage of metastatic colorectal cancer?
- What are your recommendations for involving support services (such as social work or palliative care) to help patients navigate the psychosocial components of metastatic colorectal cancer (mCRC), and at what point in a patient’s care journey does this begin?
- What is the role of the caregiver in advanced mCRC in supporting a patient through these psychosocial components?
Advertisement
Related to this article
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.
A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.
In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
4
Boston Experts Weigh Access, Sequencing, and Testing Across 4 Cancers
5